Raises FY26 Adjusted EBITDA Outlook to $120M-$124M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy GRDN?
Raises FY26 adjusted EBITDA view to $120M-$124M from $115M-$118M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 33.650
Low
34.00
Averages
34.50
High
35.00
Current: 33.650
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardian Pharmacy Services Reports Strong Q4 2025 Earnings
- Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
- Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
- Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
- Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
See More
Guardian Pharmacy (GRDN) Earnings Transcript
See More
Guardian Pharmacy Q4 Earnings Exceed Expectations
- Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
- 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
- Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
See More
Guardian Pharmacy Services Reports Strong 2025 Financial Results
- Significant Revenue Growth: Guardian Pharmacy Services reported fourth-quarter revenue of $397.6 million, a 17% year-over-year increase with organic growth of 12%, indicating strong performance in the long-term care pharmacy market and potential for increased market share.
- Substantial Net Income Increase: The company achieved a net income of $21.3 million in Q4, up 81% from $11.8 million in the prior year, reflecting successful cost control and operational efficiency, which bolsters investor confidence.
- Adjusted EBITDA Guidance Raised: Guardian raised its 2026 Adjusted EBITDA outlook to $120 million to $124 million, up from the previous guidance of $115 million to $118 million, signaling management's optimistic expectations for future performance.
- Vaccine Prescription Volume Growth: The company saw a 9% year-over-year increase in vaccine prescription volumes in 2025, vaccinating over 120,000 residents, demonstrating its commitment to public health services while enhancing brand image and customer loyalty.
See More
Guardian Pharmacy Services to Present at Raymond James Conference
- Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
- Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
- Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.
See More
Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
See More
Guardian Pharmacy Services Reports Strong Q4 2025 Earnings
- Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
- Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
- Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
- Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
See More
Guardian Pharmacy (GRDN) Earnings Transcript
See More
Guardian Pharmacy Q4 Earnings Exceed Expectations
- Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
- 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
- Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
See More
Guardian Pharmacy Services Reports Strong 2025 Financial Results
- Significant Revenue Growth: Guardian Pharmacy Services reported fourth-quarter revenue of $397.6 million, a 17% year-over-year increase with organic growth of 12%, indicating strong performance in the long-term care pharmacy market and potential for increased market share.
- Substantial Net Income Increase: The company achieved a net income of $21.3 million in Q4, up 81% from $11.8 million in the prior year, reflecting successful cost control and operational efficiency, which bolsters investor confidence.
- Adjusted EBITDA Guidance Raised: Guardian raised its 2026 Adjusted EBITDA outlook to $120 million to $124 million, up from the previous guidance of $115 million to $118 million, signaling management's optimistic expectations for future performance.
- Vaccine Prescription Volume Growth: The company saw a 9% year-over-year increase in vaccine prescription volumes in 2025, vaccinating over 120,000 residents, demonstrating its commitment to public health services while enhancing brand image and customer loyalty.
See More
Guardian Pharmacy Services to Present at Raymond James Conference
- Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
- Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
- Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.
See More
Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
See More
